BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37388735)

  • 21. Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma.
    Li S; Dong C; Chen J; Gao X; Xie X; Zhang X
    Aging (Albany NY); 2021 Jun; 13(12):16696-16712. PubMed ID: 34158412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of four biological age markers with child development: A multi-omic analysis in the European HELIX cohort.
    Robinson O; Lau CE; Joo S; Andrusaityte S; Borras E; de Prado-Bert P; Chatzi L; Keun HC; Grazuleviciene R; Gutzkow KB; Maitre L; Martens DS; Sabido E; Siroux V; Urquiza J; Vafeiadi M; Wright J; Nawrot TS; Bustamante M; Vrijheid M
    Elife; 2023 Jun; 12():. PubMed ID: 37278618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide DNA methylation profile of early-onset endometrial cancer: its correlation with genetic aberrations and comparison with late-onset endometrial cancer.
    Makabe T; Arai E; Hirano T; Ito N; Fukamachi Y; Takahashi Y; Hirasawa A; Yamagami W; Susumu N; Aoki D; Kanai Y
    Carcinogenesis; 2019 Jul; 40(5):611-623. PubMed ID: 30850842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
    Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of cerebrospinal fluid DNA methylation age during the acute recovery period following aneurysmal subarachnoid hemorrhage.
    Heinsberg LW; Liu D; Shaffer JR; Weeks DE; Conley YP
    Epigenetics Commun; 2021; 1():. PubMed ID: 35083469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer.
    Li BL; Wan XP
    J Cell Mol Med; 2020 Jul; 24(14):7767-7777. PubMed ID: 32424934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic evaluation of the novel blueprint of DNA methylation sites by integrating bulk RNA-sequencing and methylation modification data in endometrial cancer.
    Zhou H; Zhang Y; Jin J; Shen K; Yang Y; Lao P
    J Gene Med; 2024 Jan; 26(1):e3638. PubMed ID: 38011892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of endometrial cancer methylation features using combined methylation analysis methods.
    Trimarchi MP; Yan P; Groden J; Bundschuh R; Goodfellow PJ
    PLoS One; 2017; 12(3):e0173242. PubMed ID: 28278225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironment.
    Liu J; Nie S; Wu Z; Jiang Y; Wan Y; Li S; Meng H; Zhou S; Cheng W
    Genomics; 2020 Sep; 112(5):3117-3134. PubMed ID: 32474122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
    Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
    Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excavation of Molecular Subtypes of Endometrial Cancer Based on DNA Methylation.
    Liu Y; Gu Y; Zhang M; Zeng J; Wang Y; Wang H; Liu X; Liu S; Wang Z; Wang Y; Wang L; Zhang Y
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36421781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
    Salvesen HB; Das S; Akslen LA
    Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
    Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes.
    Moukarzel LA; Da Cruz Paula A; Ferrando L; Hoang T; Sebastiao APM; Pareja F; Park KJ; Jungbluth AA; Capella G; Pineda M; Levin JD; Abu-Rustum NR; Ellenson LH; Bel AV; Reis-Filho JS; Matias-Guiu X; Cadoo K; Stadler ZK; Weigelt B
    Mod Pathol; 2021 May; 34(5):994-1007. PubMed ID: 33328602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiomics profiling of the expression and prognosis of MCMs in endometrial carcinoma.
    Lan H; Yuan J; Chen X; Liu C; Guo X; Wang X; Song J; Cao K; Xiao S
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34859821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas.
    Semczuk A; Boltze C; Marzec B; Szczygielska A; Roessner A; Schneider-Stock R
    J Cancer Res Clin Oncol; 2003 Oct; 129(10):589-96. PubMed ID: 12920579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Yu L; Ji T; Liao W; Xu Y; Fang Y; Zhu Q; Nie J; Yang D
    Clin Epigenetics; 2023 Mar; 15(1):43. PubMed ID: 36932439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.